reports
Perspective Therapeutics to Participate at Upcoming May Investor Confe...
Perspective Therapeutics to Participate at Upcoming May Investor Conferences SEATTLE, May 03, 2024 (GLOBE NEWSWIRE) -- (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that members of its senior leadership team will participate in the following upcoming investor conferences as scheduled below, and will be available for one-on-one meetings with investors. Guggenheim Healthcare Talks | Radiopharmaceuticals DayDate: Monday, May 13, 2024Location: Ne...
Perspective Therapeutics to Provide Recent Business Highlights and Rep...
Perspective Therapeutics to Provide Recent Business Highlights and Report First Quarter 2024 Financial Results SEATTLE, May 02, 2024 (GLOBE NEWSWIRE) -- (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will report its first quarter 2024 financial results and provide a business update on Wednesday, May 15, 2024 before market open. The press release will be available on the newsroom section of the Company’s website at . About Perspective Therapeutics, Inc.Perspective Therapeu...
American Assets Trust, Inc. Reports First Quarter 2024 Financial Resul...
American Assets Trust, Inc. Reports First Quarter 2024 Financial Results Net income available to common stockholders of $19.3 million for the first quarter, or $0.32 per diluted share. Funds from Operations ("FFO") per diluted share increased 8% year-over-year for the first quarter to $0.71 per diluted share. Increased 2024 FFO per diluted share guidance to a range of $2.24 to $2.34 with a midpoint of $2.29, a 1% increase over prior guidance. SAN DIEGO, April 30, 2024 (GLOBE NEWSWIRE) -- American Assets Trust, Inc. (NYSE: AAT) (the ...
Perspective Therapeutics Selected by FDA to Participate in the CDRP Pr...
Perspective Therapeutics Selected by FDA to Participate in the CDRP Program to Expedite Chemistry, Manufacturing, and Controls Development Readiness for VMT-α-NET in NETs SEATTLE, April 30, 2024 (GLOBE NEWSWIRE) -- (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announces the selection of investigational product [212Pb]VMT‐α‐NET for the treatment of certain patients with neuroendocrine tumors (“NETs”) by the U.S. Food and Drug Administration (“FDA”) to participate in the Chemistry, Manufactur...
Flexsteel Industries, Inc. Reports Strong Fiscal Third Quarter 2024 Re...
DUBUQUE, Iowa--(BUSINESS WIRE)-- Flexsteel Industries, Inc. (NASDAQ: FLXS) (“Flexsteel” or the “Company”), one of the largest manufacturers, importers, and marketers of residential furniture products in the United States, today reported third quarter fiscal 2024 results. Key Results for the Third Quarter Ended March 31, 2024 Strong sales growth of 8.2%. Net sales for the quarter of $107.2 million compared to $99.1 million in the prior year quarter. Robust sales orders of $111.5 million representing growth of $12.2M, or 12.3%, compared to the prior year quarter. Significant gross mar...
Flexsteel to Appoint Derek P. Schmidt as President and CEO
DUBUQUE, Iowa--(BUSINESS WIRE)-- Flexsteel Industries, Inc. (NASDAQ:FLXS), announces the appointment of Derek P. Schmidt to the position of President and Chief Executive Officer effective July 1, 2024. Mr. Schmidt will succeed Jerald K. Dittmer who has announced his resignation from the position of Chief Executive Officer effective June 30, 2024, and retirement from Flexsteel on December 31, 2024. Derek P. Schmidt joined Flexsteel as Chief Financial Officer & Chief Operating Officer in April 2020 and was subsequently appointed Secretary and Treasurer in May 2020. In June 2022, his role as Ch...
Flexsteel Industries, Inc. to Announce Third Quarter 2024 Results on A...
DUBUQUE, Iowa--(BUSINESS WIRE)-- Flexsteel Industries, Inc. (NASDAQ:FLXS) (“Flexsteel” or the “Company”), one of the largest manufacturers, importers, and marketers of residential furniture products in the United States, announced today that it will issue its third quarter 2024 financial results after market close on Monday, April 29, 2024. A conference call and audio webcast with analysts and investors will be held on Tuesday, April 30, 2024, at 8:00 a.m. Central Time to discuss the results and answer questions. Live conference call: 833-816-1123 (domestic) or 412-317-0710 (international...
American Assets Trust, Inc. Announces First Quarter 2024 Earnings Rele...
American Assets Trust, Inc. Announces First Quarter 2024 Earnings Release Date and Conference Call Information SAN DIEGO, April 08, 2024 (GLOBE NEWSWIRE) -- American Assets Trust, Inc. (NYSE:AAT) (the “Company”) will announce its first quarter 2024 earnings in a press release to be issued after the market closes on Tuesday, April 30, 2024. Senior management will hold a conference call for its first quarter 2024 earnings on Wednesday, May 1, 2024 at 8:00 a.m. Pacific Time. To access the conference call, please dial 1 (833) 816-1162 and ask to join the American Assets Trust, Inc. Conferen...
Perspective Therapeutics to Participate at Upcoming April Investor Con...
Perspective Therapeutics to Participate at Upcoming April Investor Conferences SEATTLE, April 08, 2024 (GLOBE NEWSWIRE) -- (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced it will participate in two investor conferences in April. Thijs Spoor, Chief Executive Officer, will be participating in a panel discussion titled Radiopharmaceuticals: Energizing Disruption in Therapeutics, at the Goldman Sachs Third Annual Healthruption Conference, on April 9, 20...
Perspective Therapeutics Provides Recent Business Highlights and Repor...
Perspective Therapeutics Provides Recent Business Highlights and Reports Fiscal Year 2023 Financial Results SEATTLE, March 28, 2024 (GLOBE NEWSWIRE) -- (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today provided a business update and announced fiscal year 2023 financial results for the period ended December 31, 2023. “We made tremendous progress during 2023 in building a fully integrated radiopharmaceuticals company dedicated to advancing potentially best- or first-in-class alpha-particle therap...
Perspective Therapeutics Announces Clinical Collaboration Agreement wi...
Perspective Therapeutics Announces Clinical Collaboration Agreement with Bristol Myers Squibb to Evaluate [(212)Pb]VMT01 in Combination with Nivolumab in MC1R-Positive Metastatic Melanoma SEATTLE , March 18, 2024 (GLOBE NEWSWIRE) -- (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced a clinical trial collaboration agreement with Bristol Myers Squibb (NYSE: BMY) to evaluate the safety and tolerability of Perspective’s targeted alpha-particle therapy [212Pb]VMT01 in combination with Bristo...
Espey Increases and Declares Regular Quarterly Dividend of $0.175 Per ...
Espey Increases and Declares Regular Quarterly Dividend of $0.175 Per Share SARATOGA SPRINGS, N.Y., March 11, 2024 (GLOBE NEWSWIRE) -- The Board of Directors of Espey Mfg. & Electronics Corp. (NYSE AMERICAN: ESP) has declared a regular quarterly dividend of $0.175 per share, a 16% increase over the prior dividend. The dividend will be payable on March 28, 2024 to all shareholders of record on March 22, 2024. Espey's primary business is the development, design, and production of specialized military and industrial power supplies/transformers. The Company can be found on the Internet at...
Perspective Therapeutics to Host In-Person and Virtual Analyst Day to ...
Perspective Therapeutics to Host In-Person and Virtual Analyst Day to Discuss Targeted Alpha-Particle Radiotherapy for Cancer on March 18, 2024 SEATTLE, March 11, 2024 (GLOBE NEWSWIRE) -- ("Perspective" or "the Company") (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it will host an in-person and virtual analyst day at the New York Stock Exchange on Monday, March 18, 2024 at 10:00 AM ET. To register, . The event will feature presentations from the following members of the Compa...
Flexsteel Industries, Inc. Announces Quarterly Dividend
DUBUQUE, Iowa--(BUSINESS WIRE)-- Flexsteel Industries, Inc. (NASDAQ:FLXS), announced its Board of Directors declared a quarterly dividend of $0.15 per share, payable April 4, 2024, to shareholders of record as of March 26, 2024. Flexsteel has paid cash dividends on its common stock each year since 1938. This is the 329th consecutive quarterly cash dividend. About Flexsteel Flexsteel Industries, Inc., and Subsidiaries (the “Company”) is one of the largest manufacturers, importers, and marketers of residential furniture products in the United States. Product offerings include a wide variet...
Perspective Therapeutics Acquires CGMP-Compliant Manufacturing Facilit...
Perspective Therapeutics Acquires CGMP-Compliant Manufacturing Facility SEATTLE, March 05, 2024 (GLOBE NEWSWIRE) -- (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced the consummation of the acquisition of a state-of-the-art manufacturing facility and associated equipment and systems for the production of its 203Pb- and 212Pb-labeled radiopharmaceuticals. Previously operated by Lantheus Holdings, Inc. (“Lantheus”) (NASDAQ: LNTH), the leading radiopharmac...
Perspective Therapeutics Announces $87.4 Million Private Placement
Perspective Therapeutics Announces $87.4 Million Private Placement SEATTLE, March 04, 2024 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that it has entered into an investment agreement with a select group of institutional accredited investors, to sell securities in a private placement for aggregate gross proceeds of approximately $87.4 million, before deducting placement agent fees and other offering...
Perspective Therapeutics to Participate at Upcoming Investor Conferenc...
Perspective Therapeutics to Participate at Upcoming Investor Conferences SEATTLE, Feb. 26, 2024 (GLOBE NEWSWIRE) -- (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that management will participate at upcoming discussions and investor conferences in February and March, 2024. Fireside Chat with JonesResearch – February 28, virtualTime: 11 a.m. ETParticipant: Michael K. Schultz, Ph.D., Chief Science OfficerPlease RSVP to your JonesResearch representative...
Espey Mfg. & Electronics Corp. reports second quarter results
Espey Mfg. & Electronics Corp. reports second quarter results SARATOGA SPRINGS, N.Y., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Espey Mfg. & Electronics Corp. (NYSE American: ESP) announces results for the first six months of fiscal year 2024. Net sales for the second quarter of fiscal year 2024, October 1 to December 31, 2023, were $10,302,541 compared with last year's second quarter net sales of $8,804,109. Net income for the quarter was $1,795,370, $0.72 per diluted share, as compared to net income of $1,146,042, $0.47 per diluted share for the same quarter last year. For the first six m...
Perspective Therapeutics to Present at the Oppenheimer 34th Annual Hea...
Perspective Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference SEATTLE, Feb. 12, 2024 (GLOBE NEWSWIRE) -- (“Perspective” or “the Company”) (NYSE AMERICAN: CATX), a radiopharmaceutical company that is pioneering advanced treatment applications for cancers throughout the body, today announced that Thijs Spoor, Chief Executive Officer, will present virtually at the Oppenheimer 34th Annual Healthcare Life Sciences Conference on Wednesday, February 14, 2024, at 11:20 a.m. ET. Management will also be available for one-on-one meetings. The live webcas...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.